Cite
MLA Citation
Elisa A Rozeman et al.. “Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial.” Lancet oncology, vol. 20, no. 7, 2019, pp. 948–960. http://access.bl.uk/ark:/81055/vdc_100086502715.0x000013